Hecolin clinical trials
Also written HEV 239.
How each study uses hecolin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Norwegian Institute of Public Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Xiamen University (1) · Xiamen Innovax Biotech Co., Ltd (1)
Studies
Open first, then newest update. How each study uses hecolin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.CompletedPhase 4Norwegian Institute of Public HealthNCT02759991Written as Hecolin
- Immunogenicity and Safety of Co-immunization With Cecolin and HecolinStatus unknownPhase 4Xiamen Innovax Biotech Co., LtdNCT05415345Written as Hecolin
- Safety Study of Hepatitis E Vaccine (HEV239)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03827395Written as HEV 239
- Clinical Trial of Recombinant Hepatitis E VaccineCompletedPhase 3Xiamen UniversityNCT01014845Written as hepatitis E vaccine